ATE552012T1 - Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff - Google Patents

Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff

Info

Publication number
ATE552012T1
ATE552012T1 AT95921130T AT95921130T ATE552012T1 AT E552012 T1 ATE552012 T1 AT E552012T1 AT 95921130 T AT95921130 T AT 95921130T AT 95921130 T AT95921130 T AT 95921130T AT E552012 T1 ATE552012 T1 AT E552012T1
Authority
AT
Austria
Prior art keywords
antagonists
inhibition
active substance
abnormal growth
synovial cells
Prior art date
Application number
AT95921130T
Other languages
English (en)
Inventor
Tadamitsu Kishimoto
Masahiko Mihara
Yoichiro Moriya
Yoshiyuki Ohsugi
Original Assignee
Chugai Pharmaceutical Co Ltd
Tadamitsu Kishimoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17112746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE552012(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Tadamitsu Kishimoto filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE552012T1 publication Critical patent/ATE552012T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT95921130T 1994-10-07 1995-06-07 Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff ATE552012T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24403594 1994-10-07
PCT/JP1995/001144 WO1996011020A1 (en) 1994-10-07 1995-06-07 Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient

Publications (1)

Publication Number Publication Date
ATE552012T1 true ATE552012T1 (de) 2012-04-15

Family

ID=17112746

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95921130T ATE552012T1 (de) 1994-10-07 1995-06-07 Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff

Country Status (18)

Country Link
EP (3) EP0783893B1 (de)
JP (1) JP3067987B2 (de)
KR (1) KR100306517B1 (de)
CN (2) CN101601861A (de)
AT (1) ATE552012T1 (de)
AU (1) AU700819B2 (de)
CA (1) CA2201781C (de)
CZ (1) CZ296919B6 (de)
DK (1) DK0783893T3 (de)
ES (1) ES2384222T3 (de)
FI (1) FI120721B (de)
HU (1) HU223602B1 (de)
LU (1) LU92048I2 (de)
NO (4) NO321089B1 (de)
PL (1) PL186506B1 (de)
PT (1) PT783893E (de)
RU (1) RU2147443C1 (de)
WO (1) WO1996011020A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042377A1 (fr) * 1997-03-21 1998-10-01 Chugai Seiyaku Kabushiki Kaisha Substances servant a la prevention ou au traitement de maladies liees a la cellule-t sensibilisee contenant comme principe actif des antagonistes de l'il-6
KR20090068385A (ko) * 1997-08-15 2009-06-26 츄가이 세이야꾸 가부시키가이샤 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제
PL201461B1 (pl) 1998-03-17 2009-04-30 Chugai Pharmaceutical Co Ltd Czynnik zapobiegający lub terapeutyczny do leczenia zapalenia jelita, zawierający antagonistę IL-6 jako składnik aktywny
NZ501772A (en) 1998-04-17 2002-10-25 Suntory Ltd Gene encoding protein having aurone synthesizing activity
EP1334731B1 (de) 2000-10-25 2008-02-27 Chugai Seiyaku Kabushiki Kaisha Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
WO2002066063A1 (en) * 2001-02-23 2002-08-29 Nippon Organon K.K. Remedies for metabolic bone diseases
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
PL366469A1 (en) * 2001-04-05 2005-02-07 Immuno-Biological Laboratories Co, Ltd. Anti-osteopontin antibody and use thereof
WO2003068259A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP2007104901A (ja) * 2004-01-16 2007-04-26 Astellas Pharma Inc 関節リウマチ治療薬のスクリーニング法
JP2008505054A (ja) * 2004-02-11 2008-02-21 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｉｌ−６アンタゴニストで骨関節炎を治療する方法
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
RU2293560C2 (ru) * 2005-03-09 2007-02-20 Лидия Николаевна Долгова Способ лечения хронических гонартритов у больных остеоартрозом
RU2293559C2 (ru) * 2005-03-09 2007-02-20 Лидия Николаевна Долгова Способ подготовки к любрикантной терапии
EP3623473A1 (de) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung von polypeptiden durch regulierung der anordnung
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
EP1931383A1 (de) * 2005-09-28 2008-06-18 Cytos Biotechnology AG Interleukin-1-konjugate und ihre verwendungen
CA2625773C (en) 2005-10-14 2015-05-12 Fukuoka University Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
CN104189907A (zh) 2006-01-27 2014-12-10 学校法人庆应义塾 伴有脉络膜血管生成的疾病的治疗药
CN101479381B (zh) 2006-03-31 2015-04-29 中外制药株式会社 调控抗体血液动力学的方法
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
EP2025346B1 (de) 2006-04-07 2016-08-10 Osaka University Mittel zur förderung der muskelregeneration
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
EP2064241B1 (de) 2006-08-03 2015-10-07 Vaccinex, Inc. Monoklonale anti-il-6-antikörper und deren anwendungen
JP2010095445A (ja) * 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
EP3127921A1 (de) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstition in cdr
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
BRPI0817250A2 (pt) 2007-09-26 2014-06-17 Chugai Pharmaceutical Co Ltd Anticorpo anti-receptor da il-6.
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
HUE067049T2 (hu) 2008-04-11 2024-09-28 Chugai Pharmaceutical Co Ltd Két vagy több antigén-molekulát ismétlõdõen megkötni képes antigénkötõ molekula
CN102089326B (zh) 2008-05-13 2014-12-31 诺维莫尼公司 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
CN104906581A (zh) 2008-06-05 2015-09-16 国立研究开发法人国立癌症研究中心 神经浸润抑制剂
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP3674317B1 (de) 2009-03-19 2024-12-11 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
PE20120562A1 (es) 2009-05-15 2012-06-06 Chugai Pharmaceutical Co Ltd Anticuerpo anti-axl
JP6049455B2 (ja) * 2009-05-18 2016-12-21 ザ ユニバーシティ オブ ホンコンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｈｏｎｇ Ｋｏｎｇ 炎症性関節炎を治療するための組成物および方法
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
JP5904552B2 (ja) 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
KR20130086628A (ko) 2010-11-08 2013-08-02 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
KR102099580B1 (ko) 2010-11-17 2020-04-10 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
JP4987117B2 (ja) 2010-12-27 2012-07-25 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
EP3604330A1 (de) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-spezifischer fc-antikörper
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
EP2791169B1 (de) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Verbindungen und verfahren zur behandlung von entzündungserkrankungen
CN104349787B (zh) 2012-05-21 2019-02-15 韩国生命工学研究院 含有荔枝草提取物或其馏分作为活性成分的预防或治疗stat-3介导疾病的药物组合物
EP3009518B1 (de) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Verfahren zur vorhersage einer posttherapeutischen prognose von patienten mit schubförmig remittierender multipler sklerose (rrms) und verfahren zur bestimmung der anwendbarkeit der neuartigen therapie
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI779010B (zh) 2014-12-19 2022-10-01 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
SG11201705093UA (en) 2015-02-27 2017-07-28 Chugai Pharmaceutical Co Ltd Composition for treating il-6-related diseases
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
JP7128460B2 (ja) 2015-06-04 2022-08-31 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６阻害剤を有効成分とする精神疾患治療剤
JP7272794B2 (ja) 2015-11-03 2023-05-12 サノフィ・バイオテクノロジー ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR102784832B1 (ko) 2015-12-28 2025-03-21 추가이 세이야쿠 가부시키가이샤 Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
TW202214700A (zh) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
WO2017188356A1 (ja) 2016-04-28 2017-11-02 中外製薬株式会社 抗体含有製剤
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
CN108339118A (zh) * 2017-01-23 2018-07-31 瑞阳(苏州)生物科技有限公司 治疗或预防阻塞性睡眠呼吸暂停的药物组合物
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
EP3683234A1 (de) 2017-09-13 2020-07-22 Jiangsu Hengrui Medicine Co., Ltd. Il-6r antikörper und antigenbindendes fragment davon und medizinische verwendung
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
MX2020003472A (es) 2017-11-01 2020-08-03 Chugai Pharmaceutical Co Ltd Variante e isoforma de anticuerpos con actividad biologica reducida.
CN112955222A (zh) 2018-08-29 2021-06-11 里珍纳龙药品有限公司 用于治疗患有类风湿性关节炎的个体的方法和组合物
CN109517064B (zh) * 2018-10-10 2020-05-08 北京汇智和源生物技术有限公司 白介素-6的人源化单克隆抗体、其编码基因及应用
TW202521583A (zh) 2019-01-31 2025-06-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
KR20220088829A (ko) 2019-04-24 2022-06-28 사노피 바이오테크놀로지 류마티스 관절염의 진단 및 치료 방법
TW202110892A (zh) 2019-06-04 2021-03-16 法商賽諾菲生物技術公司 治療具有類風濕性關節炎的個體中疼痛之組成物及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
EP0399429A1 (de) * 1989-05-22 1990-11-28 Toray Industries, Inc. Monoklonaler Antikörper gegen menschliches Interleukin-6
CA2021594C (en) * 1989-07-20 2002-01-08 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
JP2898064B2 (ja) 1989-08-03 1999-05-31 忠三 岸本 ヒトｇｐ１３０蛋白質
DE3939706C1 (de) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
ES2062762T3 (es) * 1989-12-04 1994-12-16 Schering Corp Metodo para tratar el choque septico.
JP2898040B2 (ja) 1990-01-26 1999-05-31 忠三 岸本 ｇｐ１３０蛋白質に対する抗体
US5210075A (en) 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
JPH0489433A (ja) 1990-07-27 1992-03-23 Hitachi Chem Co Ltd 免疫調節剤
JP2947924B2 (ja) * 1990-11-21 1999-09-13 信和化工株式会社 光学異性体用分離剤
JPH04187645A (ja) * 1990-11-22 1992-07-06 Chuzo Kishimoto インターロイキン―６作用抑制剤
JP3370324B2 (ja) 1991-04-25 2003-01-27 中外製薬株式会社 ヒトインターロイキン−６受容体に対する再構成ヒト抗体
JPH05300338A (ja) 1992-04-17 1993-11-12 Ricoh Co Ltd 複合機
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
FR2694767B1 (fr) * 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
JPH06134617A (ja) 1992-10-23 1994-05-17 Amada Co Ltd 鋸盤の鋸刃テンション自動調整装置
JP3525221B2 (ja) * 1993-02-17 2004-05-10 味の素株式会社 免疫抑制剤

Also Published As

Publication number Publication date
CA2201781A1 (en) 1996-04-18
CA2201781C (en) 2010-01-12
EP2077120A3 (de) 2009-07-15
NO321089B1 (no) 2006-03-13
HK1127497A1 (en) 2009-09-25
EP2107070A1 (de) 2009-10-07
CN101361972A (zh) 2009-02-11
EP2077120A2 (de) 2009-07-08
DK0783893T3 (da) 2012-05-29
JPH08208514A (ja) 1996-08-13
AU700819B2 (en) 1999-01-14
ES2384222T3 (es) 2012-07-02
PL186506B1 (pl) 2004-01-30
NO2018017I1 (no) 2018-05-23
FI120721B (fi) 2010-02-15
EP0783893A4 (de) 1998-04-22
NO20055446L (no) 1997-06-04
HUT77036A (hu) 1998-03-02
CZ296919B6 (cs) 2006-07-12
NO971546L (no) 1997-06-04
JP3067987B2 (ja) 2000-07-24
CN101361972B (zh) 2011-05-25
NO971546D0 (no) 1997-04-04
NO2009009I1 (no) 2009-05-11
PT783893E (pt) 2012-05-24
NO2009009I2 (no) 2013-03-18
FI971404A0 (fi) 1997-04-04
EP0783893A1 (de) 1997-07-16
AU2630395A (en) 1996-05-02
KR100306517B1 (ko) 2001-11-30
EP0783893B1 (de) 2012-04-04
RU2147443C1 (ru) 2000-04-20
HU223602B1 (hu) 2004-10-28
WO1996011020A1 (en) 1996-04-18
FI971404L (fi) 1997-06-03
LU92048I2 (fr) 2012-09-20
CZ103497A3 (en) 1997-08-13
CN101601861A (zh) 2009-12-16
PL319574A1 (en) 1997-08-18

Similar Documents

Publication Publication Date Title
ATE552012T1 (de) Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff
RU97108276A (ru) Лечебные средства против хронического ревматоидного артрита, содержащие антагонист il-6 в качестве эффективного компонента
EA200000868A1 (ru) Ингибиторы фосфолипаз
DK0601386T3 (da) Sulfonamider
BR9907256A (pt) Inibidores beta-cetoamida de proteassoma 20s
ES2172657T3 (es) Inhibidores de trombina.
DK0533058T3 (da) Imidazo-kondenserede iso- og heterocykler som angiotensin-II-antagonister
TR200200082T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
TR199801253T2 (xx) Vitronektin resept�r� antagonistleri.
NO924326L (no) Antitrombosemidler
NO932620L (no) Amindiol-proteaseinhibitorer
ATE387215T1 (de) Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
TR199902194T2 (xx) +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
DE3485895D1 (de) Verwendung von durch emulgatoren stabilisierte kohlenwasserstoffschlaemme als brennstoffe.
EA200000768A1 (ru) ЗАМЕЩЕННЫЕ ОКСОАЗАГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ФАКТОРА Ха
EA200300834A1 (ru) Антагонисты фактора, высвобождающего кортикотропин
BR9910359A (pt) Proteìna hìbrida para inibição de desgranulação de mastócitos e seu uso
KR960013371A (ko) 약학적 혼합물
EA200000891A1 (ru) Кристаллическая форма 4-[5-метил-3-фенилизоксазол-4-ил] бензолсульфонамида
DK1032414T3 (da) Kombination af inhibitor for angiotensinomdannende enzym med et diuretikum til behandling af forstyrrelser i mikrokredsløbet
EA200100607A1 (ru) 3,4,5-тризамещенные арилнитроны и содержащие их фармацевтические композиции
DK0636247T3 (da) Fremgangsmåde og sammensætning til reduktion af virkningerne af endogen alkalisk phosphatase
DK0732926T3 (da) Farmaceutisk formulering til profylakse eller forbehandling af forgiftninger fremkaldt af organophosphor-cholinesterase-inhibitorer
EA199700223A1 (ru) Бициклические антагонисты тахикининов, их получение и применение в фармацевтической композиции
EP0336522A3 (de) Thromboxan-Antagonisten zur Verwendung in die Behandlung von hormon-bedingten Neoplasmen